Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of avapritinib in treating malignant solid tumors that
have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph
nodes (locally advanced) or other places in the body (metastatic). Avapritinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Avapritinib may
help to control the growth of malignant solid tumors.